KERN MEDICAL CENTER
1. Target Overview & Investment Thesis
KERN MEDICAL CENTER is a 222-bed under-performing / distressed in KERN, CA with $273.2M in net patient revenue and a -86.0% operating margin. The hospital serves a payer mix of 9.3% Medicare, 24.1% Medicaid, and 66.6% commercial.
Thesis: Undervalued. Our ML models identify $20.1M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -86.0% to -78.6% (+736bps).
| Net Revenue HCRIS | $273.2M |
| Current EBITDA COMPUTED | $-234.9M |
| Operating Margin COMPUTED | -86.0% |
| Occupancy HCRIS | 71.2% |
| Revenue / Bed COMPUTED | $1.2M |
| Net-to-Gross HCRIS | 23.9% |
| Distress Probability ML | 47.1% |
2. Market Context & Competitive Position
CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -86.0% places it below the state median. Among 204 size-comparable peers (111-444 beds), the median margin is -3.9%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (111-444), prioritizing same-state peers. 204 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| KERN MEDICAL CENTER (Target) | CA | 222 | $273.2M | -86.0% |
| LUCILE PACKARD CHILDRENS HOSPI | CA | 394 | $2.39B | -0.8% |
| UCI MEDICAL CENTER | CA | 397 | $1.90B | -2.5% |
| CITY OF HOPE NATIONAL MEDICAL | CA | 217 | $1.83B | -10.7% |
| RADY CHILDRENS HOSPITAL - SAN | CA | 401 | $1.82B | 14.8% |
| HARBOR-UCLA MEDICAL CENTER | CA | 369 | $1.54B | -6.4% |
| EL CAMINO HOSPITAL | CA | 388 | $1.34B | 11.7% |
| CHILDRENS HOSPITAL OF ORANGE C | CA | 334 | $1.31B | 0.7% |
| KFH - SANTA CLARA | CA | 343 | $1.25B | 12.5% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $20.1M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $5.7M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $5.5M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $5.4M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $3.3M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $175K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-234.9M |
| + RCM Uplift | +$20.1M |
| Pro Forma EBITDA | $-214.8M |
| Current Margin | -86.0% |
| Pro Forma Margin | -78.6% |
| WC Released (1x) | $10.5M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-361.3M | $-1.35B | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-361.3M | $-1.60B | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-325.2M | $-1.65B | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-325.2M | $-1.90B | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-397.5M | $-1.33B | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-397.5M | $-1.59B | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| Medium | Elevated Medicaid exposure (24.1%) | Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 204 hospitals with 111-444 beds
- Same-state prioritization (n=205)
- Comp margins: P25=-16.7% / P50=-3.9% / P75=4.6%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.